Cara Therapeutics Announces Positive Results From KALM-1 Pivotal Phase 3 Trial of KORSUVA™ Injection in Hemodialysis Patients with Pruritus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
Go back to Cara Therapeutics Announces Positive Results From KALM-1 Pivotal Phase 3 Trial of KORSUVA™ Injection in Hemodialysis Patients with Pruritus
May 29, 2019 3:40 PM EDT
Janney analyst Esther Hong raised the fair value target on Cara Therapeutics (NASDAQ: CARA) to $33.00 (from $27.00) while maintaining a Buy rating following data.
The analyst commented, "Today's announcement of positive Ph.3 KALM-1 IV-Korsuva data demonstrating statistical significance on the primary and all... More
May 29, 2019 10:55 AM EDT
H.C. Wainwright analyst Oren Livnat raised the price target on Cara Therapeutics (NASDAQ: CARA) to $28.00 (from $26.00) while maintaining a Buy rating.
...
More
May 29, 2019 8:23 AM EDT
Stifel analyst Annabel Samimy reiterated a Buy rating and $26.00 price target on Cara Therapeutics (NASDAQ: CARA) following positive top-line data from the first pivotal study (KALM-1) of IV-Korsuva in pruritus associated with chronic kidney disease (CKD-aP) in hemodialysis patients.
The study met its... More
May 29, 2019 7:04 AM EDT
Cara Therapeutics (NASDAQ: CARA) to Resume Trading at 7:30 am ET
...
More
